Program
MCV4
Its studies are mostly in Meningitis, Meningococcal · Diphtheria, led by CanSino Biologics.
Furthest: phase 4, since Jun 27, 20236 company-led studies, 3 open or runningNext primary completion: Feb 2029 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| CanSino Biologics | 63 open or running | phase 4since Jun 27, 2023 | Jun 27, 2023 | Feb 2029phase 1 · NCT07203755 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 27, 2023First study: phase 4 study in Meningitis, MeningococcalFirst studyNCT05935176 · 660 enrolled · China
- Aug 15, 2023Phase 3 study in Meningitis, MeningococcalNCT06011200 · 1,000 enrolled · China
- Jan 18, 2024Phase 3 study in Meningitis, MeningococcalNCT06226714 · 840 enrolled · China
- Apr 24, 2024Phase 4 study in Meningitis, MeningococcalNCT06389513 · 3,011 enrolled · China
- Nov 19, 2024Phase 3 study in Meningitis, MeningococcalNCT06700148 · 840 enrolled · China
- Sep 25, 2025Phase 1 study in DiphtheriaNCT07203755 · 260 planned · China
Ahead
- Feb 2029Primary completion: phase 1 study in DiphtheriaNCT07203755
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07203755Diphtheria · China | 1 | Recruiting | Feb 2029 | 260 |
| NCT06700148Meningitis, Meningococcal · China | 3 | Completed | Feb 19, 2025 | 840 |
| NCT06389513Meningitis, Meningococcal · China | 4 | Completed | Apr 10, 2026 | 3,011 |
| NCT06226714Meningitis, Meningococcal · China | 3 | Active, not recruiting | Sep 26, 2024 | 840 |
| NCT06011200Meningitis, Meningococcal · China | 3 | Completed | Dec 11, 2023 | 1,000 |
| NCT05935176Meningitis, Meningococcal · China | 4 | Active, not recruiting | May 15, 2026 | 660 |
How it is read
Names in the registry
- “MCV4”, 9 entries
Conditions, from the studies’ own filings
- Meningitis, Meningococcal, 5 studies
- Diphtheria, 1 study
First seen by our ledger Nov 14, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.